Scientists have identified molecular signatures in the immune component of the blood which indicate how patients in intensive care with sepsis, septic shock and systemic inflammatory response syndrome are likely to respond to the conditions.
Sepsis is a life-threatening condition, requiring admission to intensive care
The work – led by Public Health England and involving Nottingham Trent University and Cardiff University – means that for the first time clinicians would be able to test and pre-emptively manage and treat patients based on their immune profiles.
It is hoped that the study could also pave the way to new therapies, as the researchers were able to identify molecules that were most influential in the immune system and could therefore become druggable targets.
Sepsis is a life-threatening condition – requiring admission to intensive care – and occurs when the immune system overreacts to an infection and starts to damage the body's tissues and organs.
It is a major healthcare problem in the UK, accounting for a quarter of intensive care unit admissions.
Despite this there is a lack of knowledge of the immune processes involved in sepsis or the clinically relevant molecules at play. This would help clinicians to distinguish between sepsis and SIRS – which are very similar – to improve patient management through more appropriate treatment as well as help to identify potential new therapies.
The team analysed molecules in the white blood cells, which function as part of the immune system, of patients with sepsis, septic shock – the most severe form of sepsis – and SIRS.
Using Nottingham Trent University-led machine learning and artificial intelligence, they were then able to develop molecular signatures that were able to predict the outcome of patients based on their immune response, the condition they had and whether it had started in the lungs or the abdomen. Work is ongoing at PHE and Cardiff to further develop these signatures into clinically useful diagnostic assays.
The researchers also believe that their approach could be applied to covid-19, given that it manifests as a sepsis-like disease in the more severe cases.
This approach provides new insights into how patients respond to these serious conditions based on their immune response and the molecular processes that define and drive disease progression. Our work highlights the importance of examining these molecular immune responses in determining outcome for patients. Another important aspect of this study is that the molecular processes we identified are similar to those defining patient outcome in covid-19. As such our methods could potentially be used to predict response and outcome for these patients too.”
Professor Graham Ball, Nottingham Trent University scientist
Sepsis on the intensive care unit can present in several ways and we have learnt that defining the group of patients based on solely clinical parameters is difficult. Detailed understanding of the molecular response to infection will help us to treat those patients with novel therapies, who are most likely to benefit from these experimental approaches.”
Dr Tamas Szakmany, Senior Lecturer in Intensive Care, Cardiff University
The work, published in the journal Frontiers in Immunology, was funded by Innovate UK and also involved First City University College in Malaysia.